Lv5
905 积分 2024-09-25 加入
Five Years After Pathologic Complete Response Without Surgery-Reply
29天前
已完结
Breast Tumor-Bed Biopsy for Pathological Complete Response Prediction: The NRG-BR005 Nonrandomized Clinical Trial
29天前
已完结
Antibody–drug conjugates beyond HER2: Translating evidence into practice for HR+ HER2-negative and triple-negative metastatic breast cancer
1个月前
已完结
Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial
2个月前
已完结
Targeting IDH2 promotes antitumor immunity through epigenetic activation of cGAS-STING pathway
2个月前
已完结
Antibody–drug conjugates in gynaecological cancers: opportunities and challenges
3个月前
已完结
TROP2-Directed Antibody Drug Conjugates: New First-Line Treatment for All Patients with Advanced Triple-Negative Breast Cancer?
3个月前
已关闭
SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer
3个月前
已关闭
A Randomized Phase III Trial of Anthracyclines Followed by Taxane versus Taxane Plus Carboplatin as (Neo)Adjuvant Therapy in Patients with Triple-Negative Breast Cancer: KCSG BR 15-1 PEARLY Trial
3个月前
已完结
SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer
3个月前
已完结
皖公网安备34019202002308
